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TACROLIMUS is a potent immunosuppressive agent. It has been reported to have superior immunosuppres-
sive efficacy when compared with the standard formulation 
of cyclosporine (CyA).1 based on its ability to rescue 
patients with failing allografts under CyA-based therapy,2.3 
lower rejection rates when used as a primary immunosup-
pressive agent.45 and longer projected half-life." However. 
there have been reports of an increased incidence of 
posttransplant diabetes (PTDM) under tacrolimus-based 
therapy.4.5 We have reported on the reversibility of tacroli-
mus-induced PTDM in our own renal transplant patients.7.1< 
In this article, we present an illustrative case demonstrating 
the reversibility of PTDM and review both the published 
and unpublished literature. The data suggest that the initial 
incidence of PTDM in the renal transplant population may 
be higher under tacrolimus than under CyA-based therapy, 
but the final incidence is comparable.'J-11 
ILLUSTRATIVE CASE 
The patient was a 64-year old black female with end-stage renal 
disease secondary to hypertension. who received a kidney from her 
son. The allograft functioned immediately. and she never experi-
enced rejection. Her serum creatinine. tacrolimus dosages and 
levels. prednisone dosages. fasting blood glucose levels, and insulin 
requirements are shown in Table 1. Basically, she was normogly-
cemic until 13 weeks after transplantation. when her fasting blood 
glucose level was 2110 mgldL. One week later. it was 555 mgldL. and 
she was admitted to the hospital and started on insulin. As her 
tacrolimus and steroid dosages were tapered. her blood sugars 
normalized, and her insulin was tapered off by 2h weeks after 
transplantation. She continues to have normal renal function 1.5 
years after transplantation. with a serum creatinine of 1.0 mgldL. 
on tacrolimus I mg orally twice per day and no prednisone. Her 
tacrolimus level is 11.7 ngimL. and her fasting blood glucose is 140 
mgldL. 
Review of the Literature 
The initial and final incidences of PTDM in various studies of 
tacrolimus in renal transplantation are summarized in Table 2. The 
initial incidence ranged from 6% to 28.3%. and the final incidence 
ranged from 1.4% to 12.6%, with a reversibility of 37% to 
83%.1.4.5.12-15 Subgroup analysis was performed in only one study, 
the American Phase III Multicenter Trial. It showed a higher 
incidence of PTDM in African American than in Caucasian 
From the University of Pittsburgh Medical Center, Thomas E. 
Starzl Transplantation Institute IR.S., V.P.S., J.M., J.J.F., T.E.S.), 
Division of Urology (M.L.J., C.V., HAG., T.H.), and Division of 
General and Vascular Surgery IR.L.S.), Pittsburgh, Pennsylvania. 
Address reprint requests to Ron Shapiro, MD. 4th Floor Falk. 
3601 Fifth Avenue. Pittsburgh, PA 15213. 
Table 1. Illustrative Case of Reversible Posttransplant Diabetes (PTDM) 
Serum Tacrolimus Tacrolimus Prednisone Fasting Blood Insulin 
Creatinine Dose Level Dose Glucose (NPH/Reg.) 
Time (mg/dL) (mg/dL) (ng/mL) (mg/d) (mg/dL) (units/d) 
1 week 0.9 20 35.4 20 101 0 
1 month 1.1 20 16.3 15 106 0 
2 months 1.3 18 18.7 10 115 0 
3 months 0.9 16 14.5 10 280 0 
14 weeks 1.2 14 16.7 7.5 555 0 
16 weeks 1.0 10 10.1 5 186 25/5 
18 weeks 1.0 9 13.8 5 152 25/5 
20 weeks 1.0 7 6.3 2.5 131 20/0 
22 weeks 0.9 5 9.3 0 130 15/0 
24 weeks 0.9 5 6.7 0 126 10/0 
26 weeks 1.0 5 6.8 0 98 0 
8 months 1.0 5 7.9 0 117 0 
12 months 0.9 3 11.1 0 148 0 
18 months 1.0 2 8.7 0 140 0 
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Table 2. Tacrolimus-Associated Posttransplant Diabetes 
(PTDM) in Kidney Transplantation 
Trial Incidence Final Reversibility 
American Multicenter Phase III 19.9% 12.6% 37% 
Pittsburgh 
Adult" 18% 9% 50% 
Children 10% 1.4% 86% 
Japan 
Phase II 28.3% 4.7% 83% 
Phase III 19.3% 11.1% 42% 
European Multicenter Phase III 6% 2.5% 58% 
'Randomized trial of tacrolimuslprednisone vs tacrolimuslprednisone/aza-
thioprine. 
recipients. and an association in all patients with higher tacrolimus 
levels and steroid doses.·5 
DISCUSSION 
The diabetogenicity of tacrolimus appears to be related to a 
reversible effect of tacrolimus on islet cells. FK binding 
protein (FKBP) is present in islet cells, and decreased 
insulin transcription and secretion have been demonstrated 
experimentally.lb.17 This decrease in secretion is reversible 
when tacrolimus is discontinued. The direct islet toxicity 
can explain both the clinical phenomenon of PTDM and its 
reversibility with dose reduction. The final incidence of 
PTDM in patients receiving tacrolimus-based immunosup-
pression is not different than that reported under CyA-
based immunosuppression.'J-" The reversibility is related 
to reducing both the tacrolimus and the steroid doses. The 
relatively lower reversibility in the American Phase III 
Multicenter Trial is probably related to a protocol-driven 
minimum dose of prednisone in that trial.-u 
Given the improved immunosuppressive efficacy associ-
ated with tacrolimus. 1-(, the transiently increased incidence 
of PTDM may well be considered clinically acceptable. 
Certainly. the potential for PTDM has not prevented the 
successful use of tacrolimus in kidney/pancreas transplan-
tation. where a number of reports have described its 
t: fficacy. I K. I 'J 
When PTDM does occur under taerolimus-based ther-
apy. it is important not to reduce tht: dosage too quieklv 
hecause al.:ute rt:jel.:tion can OCI.:Ur. A gradual reduction in 
hoth tacrolimus and steroids will allow continued good graft 
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function. and can lead to a normalization of blood sugars 
with the eventual discontinuation of insulin. 
In summary, while PTDM is a potential complication of 
tacrolimus. it is often reversible with dosage reduction of 
both tacrolimus and steroids. The final incidence of ProM 
is not different than that reported under CyA-based immu-
nosuppression. Thus. the concern about PTDM should not 
deter physicians from using tacrolimus-based therapy for 
their patients. 
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